"Designing Growth Strategies is in our DNA"

Biosimilars Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Peg-filgrastim, Monoclonal Antibodies, and Others), By Disease Indication (Cancer, Autoimmune Diseases {Arthritis, Psoriasis, and Others}, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030

Last Updated: December 02, 2024 | Format: PDF | Report ID: FBI108928

 

  1. Introduction
    1. Market Scope
    2. Market Segmentation
    3. Market Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, By Key Countries/Regions, 2022
    2. New Product Launches, By Key Players
    3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
    4. Regulatory Scenario, Key Countries/Regions
    5. Pipeline Analysis, By Key Players
    6. Impact of COVID-19 on the Market
  5. Global Biosimilars Market Analysis, Insights and Forecast, 2017-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Biosimilars Market Analysis, Insights and Forecast, 2017-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Other Facilities
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
        1. By Drug Class
      2. Canada
        1. By Drug Class
  7. Europe Biosimilars Market Analysis, Insights and Forecast, 2017-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
        1. By Drug Class
      2. Germany
        1. By Drug Class
      3. France
        1. By Drug Class
      4. Italy
        1. By Drug Class
      5. Spain
        1. By Drug Class
      6. Scandinavia
        1. By Drug Class
      7. Rest of Europe
        1. By Drug Class
  8. Asia Pacific Biosimilars Market Analysis, Insights and Forecast, 2017-2030
    1. Market Analysis, Insights and Forecast – By Disease Indication
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. China
        1. By Drug Class
      2. India
        1. By Drug Class
      3. Japan
        1. By Drug Class
      4. Australia
        1. By Drug Class
      5. Southeast Asia
        1. By Drug Class
      6. Rest of Asia Pacific
        1. By Drug Class
  9. Latin America Biosimilars Market Analysis, Insights and Forecast, 2017-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
        1. By Drug Class
      2. Mexico
        1. By Drug Class
      3. Rest of Latin America
        1. By Drug Class
  10. Middle East & Africa Biosimilars Market Analysis, Insights and Forecast, 2017-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Filgrastim & Peg-filgrastim
      2. Monoclonal Antibodies
      3. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Cancer
      2. Autoimmune Diseases
        1. Arthritis
        2. Psoriasis
        3. Others
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
        1. By Drug Class
      2. South Africa
        1. By Drug Class
      3. Rest of Middle East & Africa
        1. By Drug Class
  11. Competitive Analysis
    1. Global Market Share Analysis (2022)
    2. Company Profiles
      1. Celltrion Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Novartis AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Amgen Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Biocon
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Biogen
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Coherus BioSciences
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Samsung Bioepis
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Shanghai Henlius Biotech, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 01: Global Biosimilars Market Revenue Breakdown (USD billion, %) by Region, 2022 & 2030

Figure 02: Global Biosimilars Market Value Share (%), by Drug Class, 2022 & 2030

Figure 03: Global Biosimilars Market Value Share (%), by Disease Indication, 2022 & 2030

Figure 04: Global Biosimilars Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 05: Global Biosimilars Market Value (USD billion), by Region, 2022 & 2030

Figure 06: North America Biosimilars Market Value (USD billion), By Drug Class, 2022 & 2030

Figure 07: North America Biosimilars Market Value Share (%), By Drug Class, 2022

Figure 08: North America Biosimilars Market Value (USD billion), By Disease Indication, 2022 & 2030

Figure 09: North America Biosimilars Market Value Share (%), By Disease Indication, 2022

Figure 10: North America Biosimilars Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 11: North America Biosimilars Market Value Share (%), by Distribution Channel, 2022

Figure 12: North America Biosimilars Market Value (USD billion), By Country, 2022 & 2030

Figure 13: North America Biosimilars Market Value Share (%), By Country, 2022

Figure 14: Europe Biosimilars Market Value (USD billion), By Drug Class, 2022 & 2030

Figure 15: Europe Biosimilars Market Value Share (%), By Drug Class, 2022

Figure 16: Europe Biosimilars Market Value (USD billion), By Disease Indication, 2022 & 2030

Figure 17: Europe Biosimilars Market Value Share (%), By Disease Indication, 2022

Figure 18: Europe Biosimilars Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 19: Europe Biosimilars Market Value Share (%), by Distribution Channel, 2022

Figure 20: Europe Biosimilars Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 21: Europe Biosimilars Market Value Share (%), By Country/ Sub-region, 2022

Figure 22: Asia Pacific Biosimilars Market Value (USD billion), By Drug Class, 2022 & 2030

Figure 23: Asia Pacific Biosimilars Market Value Share (%), By Drug Class, 2022

Figure 24: Asia Pacific Biosimilars Market Value (USD billion), By Disease Indication, 2022 & 2030

Figure 25: Asia Pacific Biosimilars Market Value Share (%), By Disease Indication, 2022

Figure 26: Asia Pacific Biosimilars Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 27: Asia Pacific Biosimilars Market Value Share (%), by Distribution Channel, 2022

Figure 28: Asia Pacific Biosimilars Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 29: Asia Pacific Biosimilars Market Value Share (%), By Country/ Sub-region, 2022

Figure 30: Latin America Biosimilars Market Value (USD billion), By Drug Class, 2022 & 2030

Figure 31: Latin America Biosimilars Market Value Share (%), By Drug Class, 2022

Figure 32: Latin America Biosimilars Market Value (USD billion), By Disease Indication, 2022 & 2030

Figure 33: Latin America Biosimilars Market Value Share (%), By Disease Indication, 2022

Figure 34: Latin America Biosimilars Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 35: Latin America Biosimilars Market Value Share (%), by Distribution Channel, 2022

Figure 36: Latin America Biosimilars Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 37: Latin America Biosimilars Market Value Share (%), By Country/ Sub-region, 2022

Figure 38: Middle East & Africa Biosimilars Market Value (USD billion), By Drug Class, 2022 & 2030

Figure 39: Middle East & Africa Biosimilars Market Value Share (%), By Drug Class, 2022

Figure 40: Middle East & Africa Biosimilars Market Value (USD billion), By Disease Indication, 2022 & 2030

Figure 41: Middle East & Africa Biosimilars Market Value Share (%), By Disease Indication, 2022

Figure 42: Middle East & Africa Biosimilars Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 43: Middle East & Africa Biosimilars Market Value Share (%), by Distribution Channel, 2022

Figure 44: Middle East & Africa Biosimilars Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 45: Middle East & Africa Biosimilars Market Value Share (%), By Country/ Sub-region, 2022

Figure 46: Global Biosimilars Market Share (%), By Company, 2022

Table 01: Global Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 02: Global Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2017-2030

Table 03: Global Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2030

Table 04: Global Biosimilars Market Revenue (USD billion) Forecast, by Region, 2017-2030

Table 05: North America Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 06: North America Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2017-2030

Table 07: North America Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2030

Table 08: North America Biosimilars Market Revenue (USD billion) Forecast, By Country, 2017-2030

Table 09: U.S. Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 10: Canada Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 11: Europe Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 12: Europe Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2017-2030

Table 13: Europe Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2030

Table 14: Europe Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2030

Table 15: U.K. Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 16: Germany Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 17: France Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 18: Italy Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 19: Spain Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 20: Scandinavia Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 21: Rest of Europe Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 22: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 23: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2017-2030

Table 24: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2030

Table 25: Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2030

Table 26: China Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 27: India Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 28: Japan Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 29: Australia Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 30: Southeast Asia Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 31: Rest of Asia Pacific Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 32: Latin America Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 33: Latin America Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2017-2030

Table 34: Latin America Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2030

Table 35: Latin America Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2030

Table 36: Brazil Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 37: Mexico Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 38: Rest of Latin America Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 39: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 40: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Disease Indication, 2017-2030

Table 41: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2030

Table 42: Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2030

Table 43: GCC Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 44: South Africa Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Table 45: Rest of Middle East & Africa Biosimilars Market Revenue (USD billion) Forecast, By Drug Class, 2017-2030

Biosimilars Market Size, Share and Global Industry Trend Forecast till 2030
  • 2017-2030
  • 2022
  • 2017-2021
  • 150
  • Buy Now

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Related Reports

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X